CD274 and neoplasm: After several years of great efforts in the immunotherapy biomarker space, today, there are only two predictive biomarkers endorsed to guide decision-making about prescribing checkpoint inhibitors: expression of the programmed death-ligand 1 (PDL-1) and the microsatellite instability (MSI) status of the tumor.